UNC, Harvard develop inhaled TB vaccineMarch 17, 2008CHAPEL HILL - A new tuberculosis vaccine successfully tested at the University of North Carolina at Chapel Hill is easier to administer and store and just as effective as one commonly used worldwide. Scientists at the UNC School of Pharmacy led by Tony Hickey, Ph.D., vetted a dry powder vaccine provided by Harvard University that is administered using an inhaler. The results of the vaccine test are being published this week in the Proceedings of the National Academy of Sciences. "It is at least as good as the injectable vaccine," said Hickey, a professor in the School's molecular pharmaceutics division. "The real advantage is that this vaccine does not need to be refrigerated. It also doesn't require needles, syringes and water like the injectable vaccine, and administering it is as easy as breathing in, making it ideal for use in developing countries."
The vaccine is spray dried instead of freeze dried. Spray drying is the process of spraying a liquid through a heated gas such as nitrogen to create a powder. Traditional TB vaccines are freeze dried, requiring refrigerated storage and transportation, and a source of clean water to reconstitute the vaccine for injection. Spray dried vaccines do not need refrigeration or water to be used. Hickey's group specializes in developing drugs and vaccines that can be inhaled as a dry powder. The vaccine used in the study was a Bacillus Calmette-Guérin (BCG) vaccine, which is not common in the United States but is used extensively throughout the world. Given to 100 million infants annually, the current BCG vaccine for TB is the world's most widely administered childhood vaccine. According to the Centers for Disease Control and Prevention, tuberculosis is one of the deadliest diseases, infecting a third of the world's population. Each year nearly nine million people become sick with TB and almost two million of them die. Hickey, who is an expert in the delivery of vaccines and medicines via dry aerosol, said that breathing in a TB vaccine is beneficial because inhalation is the way tuberculosis is contracted. He also believes that the successful test of this vaccine could affect the development of others. "The results of this study are very exciting because there are other bacterial vaccines being developed that might benefit from this technology," he said. Hickey is a co-founder of Oriel Therapeutics, a company developing dry-powder inhaler products to effectively deliver medicines to the lungs to treat a wide range of respiratory diseases, such as asthma and chronic obstructive pulmonary disease. He is also the founder, president and CEO of Cirrus Pharmaceuticals. Both companies are located in North Carolina's Research Triangle Park. University of North Carolina at Chapel Hill | |||||||||||||||||||||
|
Related Tuberculosis News Articles New method to overcome multiple drug resistant diseases developed by Stanford researchers Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them. India continues to progress in AIDS vaccine development efforts A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated. Extensively drug-resistant tuberculosis found in California In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB. The study appears in the August 15 issue of Clinical Infectious Diseases, now available online. Comprehensive treatment of extensively drug-resistant TB works, study finds The death sentence that too often accompanies a diagnosis of extensively drug-resistant tuberculosis (XDR-TB) can be commuted if an individualized outpatient therapy program is followed - even in countries with limited resources and a heavy burden of TB. Treatment outcomes highlight dangers of extensively drug-resistant tuberculosis In a retrospective study of 174 tuberculosis patients treated at National Jewish Health (formerly National Jewish Medical and Research Center), patients with extensively-drug-resistant tuberculosis (XDR-TB) were almost eight times as likely to die as patients with multi-drug resistant tuberculosis (MDR-TB). Ben-Gurion University of the Negev initiates project to eliminate intestinal worms in Ethiopia A professor at The Faculty of Health Sciences at Ben-Gurion University of the Negev (BGU) is beginning an intensive program in Ethiopia this August to eradicate intestinal worms which affect as much as 50 percent of the population in Africa. Certain HIV treatment less effective when used with anti-TB therapy Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy. Study helps identify which populations of foreign-born persons living in US at higher risk of TB The relative yield of finding and treating latent tuberculosis is particularly high among higher-risk groups of foreign-born persons living in the U.S., such as individuals from most countries of sub-Saharan Africa and Southeast Asia. Tuberculosis presents major challenges to HIV treatment in developing countries Human immunodeficiency virus (HIV) care and treatment programs in resource-limited settings must aggressively address tuberculosis (TB) and the emerging multidrug-resistant TB epidemic to save patient lives and to curb the global TB burden, a major cause of death for persons with HIV. Bovine tuberculosis in wildlife threatens endangered lynx and cattle health In an epidemiological survey of Spain's Doñana National Park, the findings of which are published on July 23 in the journal PLoS ONE, Christian Gortázar and colleagues studied the prevalence of bovine tuberculosis (bovine TB) infection among populations of wild boar, red deer and fallow deer in the national park, which is located in southern Spain. More Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||